“The advancement of novel therapies like CAR-T in relapsed and refractory pediatric B-ALL is truly a beacon of hope for children and young adults with a previously dismal prognosis.”

BUFFALO, NY - May 17, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “The price of hope: CAR-T therapy in pediatric leukemia.”

We stand at the crossroads of medical innovation, where cutting-edge scientific discoveries intersect with the resilience of

BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncoscience is one of the most prominent journals published by Impact Journals.

Impact Journals is proud to participate as an exhibitor at the Society for Scholarly Publishing (SSP) 46th Annual Meeting, which convenes in Boston, Massachusetts, at the Westin Boston Seaport District from May 29–31, 2024. This year, the SSP Annual

“These results argue that combinations based on immunotherapy may also provide an opportunity for targeting urothelial cancers with low TMB, and provide efficacy superior to classic chemotherapy.”

BUFFALO, NY - May 10, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.”

In this new editorial, researcher Ioannis A. Voutsadakis from Sault Area Hospital

“[...] this editorial underscores the complex molecular diagnosis landscape of cancer in the [Latin American] population.”

BUFFALO, NY - May 03, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 22, 2024, entitled, “Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding.”

In this editorial, researcher Rafael Parra-Medina from Fundación Universitaria de Ciencias de la Salud

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncoscience is one of the most prominent journals published by Impact Journals.

Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring

“Given that the MET inhibitor capmatinib caused a remarkable response in Dr. Blagosklonny, a pertinent question remains as to why he was not treated with ‘preemptive drug combinations’ [...]”

BUFFALO, NY - February 23, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on February 9, 2024, entitled, “A very long and winding road: developing novel therapeutics for metastatic tumors.”

In this editorial, researcher Paul Dent from the Department of Biochemistry and

“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”

BUFFALO, NY - February 9, 2024 – A new research perspective was recently published in Oncoscience (Volume 11) on February 7, 2024, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed

“Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.”

BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.”

“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I... continue reading >>